Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
The open-house model is not subject to procurement law; potential legal uncertainty regarding contract stability.
No indication of discount rates or market size; profitability depends on negotiated discounts and volume.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Provision of Certolizumab pegol (ATC L04AB05) under a discount agreement with AOK Bayern
- Agreement to a fixed discount model; terms are predefined and non-negotiable
Show full summary
This is an open-house model (not a formal procurement procedure) by AOK Bayern for non-exclusive discount agreements on the pharmaceutical active substance Certolizumab pegol (ATC L04AB05). Any interested pharmaceutical company that meets the eligibility criteria can join. The contract duration is from 01.06.2025 to 31.05.2027. No estimated value is provided. Submission can be in paper form or electronically with a qualified electronic signature. The contract is automatically terminated if a regular procurement discount agreement for the same substance comes into effect.
Risks
The open-house model is not subject to procurement law; potential legal uncertainty regarding contract stability.
No indication of discount rates or market size; profitability depends on negotiated discounts and volume.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company (pharmazeutischer Unternehmer)
Administrative
- Submit signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Submit signed contract and attachment specifying the medicinal products
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05
Non-exclusive discount agreements for Certolizumab pegol. Open to all qualified pharmaceutical companies. Contracts are identical and non-negotiable.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 15 Apr 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 246855-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
The open-house model is not subject to procurement law; potential legal uncertainty regarding contract stability.
No indication of discount rates or market size; profitability depends on negotiated discounts and volume.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications